BridgeBio Oncology Therapeutics (BBOT) Assets Average (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Assets Average of $433.0 million for Q1 2026, down 7.2% sequentially from $466.6 million in Q4 2025, and up 140.58% YoY from $180.0 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Assets Average (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Assets Average for 3 years, with the latest figure at $433.0 million in Q1 2026.
- Quarterly Assets Average rose 140.58% year-over-year to $433.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $433.0 million (up 140.58% YoY) and the FY2025 annual result came in at $306.3 million, up 272.15% from the prior year.
- Assets Average declined to $433.0 million in Q1 2026 per BBOT's latest filing, from $466.6 million in the prior quarter.
- Over five years, Assets Average peaked at $466.6 million in Q4 2025 and troughed at $93.9 million in Q1 2024.
- A 3-year average of $252.1 million and a median of $191.1 million in 2024 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 161.66% in 2025, down 4.15% in 2025.
- Over 3 years, Assets Average stood at $178.3 million in 2024, then soared by 161.66% to $466.6 million in 2025, then dropped by 7.2% to $433.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $433.0 million, $466.6 million, and $341.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 397.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 397.18 Mn |
| Mar 31, 2026 | 433.01 Mn |
| Dec 31, 2025 | 466.59 Mn |
| Sep 30, 2025 | 341.09 Mn |
| Jun 30, 2025 | 196.53 Mn |
| Mar 31, 2025 | 179.99 Mn |
| Dec 31, 2024 | 178.32 Mn |
| Sep 30, 2024 | 191.10 Mn |
| Jun 30, 2024 | 188.70 Mn |
| Mar 31, 2024 | 93.93 Mn |